On November 9, 2026 AbelZeta Inc. ("AbelZeta" or the "Company"), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, reported updated clinical results from the first-in-human study investigating C-CAR031 (now known as AZD7003), a novel glypican-3 (GPC3)-targeted armored CAR-T in advanced hepatocellular carcinoma (HCC), presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) Congress 2026 in Madrid, Spain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation reported an encouraging survival signal and antitumor activity in 36 heavily pretreated patients with advanced HCC, who had received a median of four prior lines of systemic therapy. As of the August 15, 2026 data cutoff date, median follow-up was 14.9 months.

Presentation Details

Abstract: 1680RO
Title: Phase I study of C-CAR031 (AZD7003), a GPC3-targeted TGFβRIIDN armored autologous CAR-T, in advanced hepatocellular carcinoma: Updated results
Session: Rapid Oral Presentation – Cell Therapy
Date: October 26, 2026
Key Clinical Results

Baseline Characteristics: The study enrolled advanced HCC patients with the majority (94.4%) of patients at Barcelona Clinic Liver Cancer (BCLC) Stage C, with extrahepatic lesions (83.3%). Patients were heavily pre-treated with a median of 4 lines of systemic therapies, with the majority (91.7%) of patients having received both immunotherapy and VEGF(R) inhibitors before enrollment.
Safety: Most patients experienced mild (Grade 1 or 2) cytokine release syndrome (CRS), with two patients (5.6%) at the highest dose level experiencing Grade 3 CRS. No dose-limiting toxicities (DLTs), immune effector cell-associated neurotoxicity syndrome (ICANS), or immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) were observed. Two patients (5.6%) at the highest dose level had interstitial lung disease (ILD).
Clinical activities: The confirmed overall response rate was 44.4% and the disease control rate (DCR) was 91.7% across all 4 dose levels. At the recommended phase 2 dose (RP2D) of 2.5×10^6 cells/kg, the DCR was 100% with a 12-month overall survival rate of 75.6%. Previously published data reported that tumor regression was observed in 32/36 patients (88.9%) across both intrahepatic and extrahepatic lesions.
"These updated results provide further encouraging clinical evidence of the potential of C-CAR031/AZD7003 to address significant unmet medical needs in advanced hepatocellular carcinoma, particularly among patients who have exhausted multiple lines of treatment," said Tony (Bizuo) Liu, Chairman and Chief Executive Officer of AbelZeta. "We are proud of the important role AbelZeta has played in advancing this program, combining AstraZeneca’s innovative CAR-T design and armoring technology with our extensive cell therapy engineering, manufacturing, and clinical development capabilities. We are pleased to see the continued clinical progress of this program under AstraZeneca’s global leadership and look forward to its further development for patients with HCC."

C-CAR031/AZD7003 is an autologous GPC3-targeting CAR-T therapy designed by AstraZeneca using its dominant-negative transforming growth factor-beta receptor II (dnTGFβRII) armoring platform, that is designed to overcome immunosuppression within the solid tumor microenvironment. The first-in-human clinical study was conducted by The First Affiliated Hospital, Zhejiang University School of Medicine, led by Professor Tingbo Liang and Dr. Qi Zhang.

In January 2026, AbelZeta announced an agreement under which AstraZeneca acquired AbelZeta’s remaining development and commercialization rights to C-CAR031 in China. AstraZeneca now holds sole worldwide rights to develop, manufacture, and commercialize the investigational therapy, while AbelZeta remains eligible to receive development, regulatory, and commercial milestone payments, as well as royalties under the applicable agreements.

(Press release, AbelZeta, NOV 9, 2026, View Source [SID1234674494])

On November 9, 2026 Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of an investigational, potentially first-in-class WEE1 inhibitor, azenosertib, as a biomarker-driven treatment approach for ovarian cancer, reported financial results for the third quarter ended September 30, 2026, and highlighted recent business updates.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Overall survival data from DENALI Part 1b presented at ESMO (Free ESMO Whitepaper) reinforce our confidence in azenosertib to offer a differentiated oral treatment for patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC), if approved," said Julie Eastland, Chief Executive Officer of Zentalis Pharmaceuticals. "We designed complementary paths through DENALI and ASPENOVA to support our goal of bringing azenosertib to patients as quickly as possible. In light of an evolving landscape in PROC, we plan to discuss the DENALI data with the FDA in 2027 to assess the accelerated approval opportunity. Meanwhile, we continue to advance ASPENOVA at full speed, ensuring we are well positioned to support our regulatory strategy under either an accelerated or full approval pathway. With DENALI Part 2c enrollment completing this month, we expect a topline readout from DENALI in the first half of 2027 — a key potential value-creating catalyst ahead of ASPENOVA.

Ms. Eastland continued: "Alongside our PROC program, our strategy includes advancing azenosertib as a combination therapy where we see meaningful therapeutic and scientific rationale. MUIR, evaluating azenosertib in combination with bevacizumab in platinum-sensitive ovarian cancer, is enrolling. Additionally, we are actively planning a combination clinical study in triple-negative breast cancer. Collectively, this strategy positions azenosertib to realize its full potential, both as the first targeted option for patients with Cyclin E1-positive PROC and through combinations across tumor types where WEE1 inhibition may enhance the benefit of standard-of-care therapies, including ADCs and other agents.

"With $228.9 million on the balance sheet providing an anticipated runway into the first half of 2028, we believe we are well resourced to support key DENALI milestones, full enrollment in ASPENOVA and combination trials in ovarian cancer and triple-negative breast cancer," Ms. Eastland concluded.

Business Updates
Clinical Development
•DENALI Part 2 Enrollment Completing: Enrollment in DENALI Parts 2a and 2b is complete and enrollment in Part 2c is scheduled to complete in November 2026.
•DENALI Part 2 Topline Readout: Zentalis expects to provide a topline readout in the first half of 2027 which will reflect an integrated dataset across Parts 2a, 2b, and 2c.
•ASPENOVA Phase 3 Enrolling: We continue to execute on the global Phase 3 ASPENOVA study, with trial site initiations and enrollment advancing across multiple geographies.
•MUIR Phase 1b Enrolling: Enrollment in Part 2 is ongoing for azenosertib in combination with bevacizumab as the maintenance treatment for second-line platinum-sensitive ovarian cancer.
•Triple-Negative Breast Cancer Combination Study Planning: Zentalis is actively planning a combination clinical study of azenosertib in triple-negative breast cancer.

Congresses and Publications
•European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2026: In October 2026, the following were presented:
◦DENALI Part 1b Overall Survival Analysis: Meaningful overall survival data from DENALI Part 1b were presented at the ESMO (Free ESMO Whitepaper) Annual Meeting, further supporting the biomarker-driven development strategy. In Cyclin E1-positive PROC patients (n=48), median OS was 15.9 months (95% CI, 8.7–21.2), versus 7.5 months (95% CI, 5.8-12.3) in Cyclin E1-negative patients (n=46). Updated ORR in response-evaluable Cyclin E1-positive patients was 37.2%, with a median DOR of 5.5 months, including two patients with responses exceeding 15 and 20 months. The safety profile was consistent with prior reporting; median relative dose intensity was 84.6%.
◦ASPENOVA Trial-in-Progress: An overview of the ongoing Phase 3 ASPENOVA trial evaluating azenosertib in patients with Cyclin E1-positive PROC.
•College of American Pathologists Annual Meeting — Cyclin E1 IHC Assay Validation: In October 2026, Zentalis scientists presented analytical validation data for a laboratory-developed IHC test for Cyclin E1 detection in high-grade serous ovarian cancer, demonstrating high concordance across laboratories and readers and supporting prospective biomarker screening in ongoing clinical trials.
Corporate
•Follow-on Equity Offering: In August 2026, completed a follow-on offering of 26,450,000 shares of common stock, raising approximately $86.9 in net proceeds.

Third Quarter 2026 Financial Results
•Cash Position: Cash, cash equivalents and marketable securities were $228.9 million as of September 30, 2026, compared to $174.6 million as of June 30, 2026, including net proceeds from the August 2026 follow-on offering. Zentalis believes that existing cash, cash equivalents and marketable securities will be sufficient to fund operating expenses and capital expenditure requirements into the first half of 2028.
•Research and Development Expenses: Research and development expenses for the three months ended September 30, 2026 were $22.3 million, compared to $23.0 million for the three months ended September 30, 2025. The $0.7 million decrease was primarily attributable to a $6.2 million decrease in clinical trial expenses for certain studies that reached or are near completion, partially offset by a $3.8 million increase in expenses for ongoing clinical trials open for enrollment, a $0.8 million increase in companion diagnostic development expenses and a $0.9 million increase in personnel-related expenses and allocated overhead.
•General and Administrative Expenses: General and administrative expenses for the three months ended September 30, 2026 were $8.8 million, compared to $10.8 million for the three months ended September 30, 2025. The $2.0 million decrease was primarily attributable to a $2.7 million decrease in personnel-related expenses partially offset by a $0.7 million increase primarily related to consulting and outside services.
•Total Operating Expenses: Total operating expenses were $31.2 million for the three months ended September 30, 2026, compared to $33.7 million for the three months ended September 30, 2025.

About Azenosertib
Azenosertib is an investigational, potentially first-in-class, selective, and orally bioavailable inhibitor of WEE1 currently being evaluated in clinical studies in ovarian cancer and additional tumor types. WEE1 acts as a master regulator of the G1-S and G2-M cell cycle checkpoints, through negative regulation of both CDK1 and CDK2, to prevent replication of cells with damaged DNA. By inhibiting WEE1, azenosertib enables cell cycle progression, despite high levels of DNA damage, thereby resulting in the accumulation of DNA damage and leading to mitotic catastrophe and cancer cell death.

Azenosertib is in late-stage development as a potential treatment for Cyclin E1-positive PROC. There is currently no approved treatment option specifically for this biomarker-selected population which comprises approximately 50% of PROC patients. Cyclin E1 protein overexpression has been established as a sensitive and specific predictive biomarker for identifying patients who could potentially derive benefit from azenosertib treatment.

Azenosertib has not been approved by the U.S. Food and Drug Administration or any other regulatory authority.

About DENALI Clinical Trial
DENALI is a multi-part Phase 2 clinical trial (NCT05128825) studying azenosertib in PROC patients.

Part 1b enrolled patients with PROC regardless of Cyclin E1 protein expression, all treated at 400mg QD 5:2. Part 2 is prospectively enrolling PROC patients with Cyclin E1 protein overexpression based on Zentalis’ proprietary immunohistochemistry cutoff.

Part 2, in total, was designed to support an accelerated approval pathway in the Cyclin E1-positive patient population, subject to the strength of the data, FDA feedback and the treatment landscape at the time of regulatory action.

•Part 2a: Dose confirmation evaluated two doses, 300mg QD 5:2 and 400mg QD 5:2, with approximately 30 patients enrolled per dose group. 400mg QD 5:2 was selected as the optimal monotherapy dose. Recruitment at the 300mg QD 5:2 dose level has been discontinued. All patients enrolled in Part 2a will contribute to the overall safety database submitted to the FDA.
•Part 2b: Enrollment expansion at the selected 400mg QD 5:2 dose up to approximately 100 patients, including patients at this dose in Part 2a. This cohort has completed enrollment.
•Part 2c: Broadening study population to include patients previously treated with a taxane-containing regimen for PROC. The enrollment in this cohort is scheduled to complete in November 2026.
For physician and patient information about the DENALI trial, please visit www.denalitrial.com.

About ASPENOVA Clinical Trial
ASPENOVA is a Phase 3 randomized, confirmatory clinical trial designed to support full approval of azenosertib in patients with Cyclin E1-positive PROC. The trial is expected to enroll approximately 420 patients and compare azenosertib monotherapy at 400mg QD 5:2 to investigator’s choice of standard-of-care single-agent chemotherapy (paclitaxel, pegylated liposomal doxorubicin [PLD], gemcitabine, or topotecan) in this biomarker-selected population. The primary endpoint is progression-free survival (PFS); key secondary endpoints include overall survival (OS) and overall response rate (ORR). ASPENOVA is intended to support approvals in the U.S. and major ex-U.S. markets, based on alignment with U.S. and EU regulators.

(Press release, Zentalis Pharmaceuticals, NOV 9, 2026, View Source [SID1234674489])

On November 9, 2026 Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), a biopharmaceutical company that has developed conditionally activated therapeutics engineered to stimulate the body’s immune system for the treatment of cancer, reported new clinical data from its Phase 1/1b clinical trial of WTX-124 and its Phase 1b/2 clinical trial of WTX-330, its conditionally activated Interleukin-2 (IL-2) and Interleukin-12 (IL-12) INDUKINETM molecules, respectively, for the treatment of solid tumors, as presented by posters at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 2026 Annual Meeting from November 6-8, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Werewolf is extremely proud of the team that designed the WTX-124 and WTX-330 molecules and shepherded them through their first-in-human clinical trials. The data presented at SITC (Free SITC Whitepaper) demonstrated that both molecules were administered in the outpatient setting with no evidence of vascular leak syndrome or recurrence of prior immune-related adverse events, and each molecule showed evidence of clinical activity in patients with advanced, treatment refractory disease. We would like to express our gratitude to the patients who participated in both of these clinical studies, as well as to the investigators and their study teams. Werewolf continues to explore opportunities for the further clinical development of the WTX-124 and WTX-330 programs." said Daniel J. Hicklin, Ph.D., President and Chief Executive Officer of Werewolf.

The Phase 1/1b clinical trial of WTX-124 evaluated WTX-124 as a monotherapy and in combination with pembrolizumab in patients with relapsed/refractory, immunotherapy-sensitive locally advanced or metastatic solid tumors who were refractory to or intolerant of standard of care treatment. The presentation at SITC (Free SITC Whitepaper) reported data from 155 patients: 65 patients treated in Part 1 (dose escalation), 42 with 1-28 mg WTX-124 IV Q2W monotherapy and 23 with WTX-124 1-23 mg IV Q2W combined with pembrolizumab 400 mg IV Q6W; and an additional 90 patients treated in Part 2 (dose expansion) with the WTX-124 recommended phase 2 dose as monotherapy (n=49) or in combination with pembrolizumab (n=41). All patients had previously received standard of care immune-checkpoint inhibitor (ICI) regimens.

Data for the Phase 1/1b clinical trial of WTX-124, as of the June 4, 2026, clinical database lock date, are summarized as follows:

•
In dose escalation, WTX-124 as a monotherapy produced three objective responses in dose escalation, including one durable confirmed complete response (CR) in a patient with primary immune checkpoint inhibitor (ICI)-resistant cutaneous squamous cell carcinoma (CSCC) that has remained ongoing without any additional anticancer therapy for approximately three years, and two partial responses in patients with cutaneous melanoma and gastroesophageal junction (GEJ) adenocarcinoma per immune RECIST. Additional patients with non-small cell lung cancer (NSCLC), mucosal melanoma and GEJ adenocarcinoma showed evidence of durable target lesion regression spanning 3-13 months.

•
In dose escalation, WTX-124 in combination with pembrolizumab produced a confirmed CR and a confirmed partial response ongoing at the end of the study (i.e., 24 months), in patients with cutaneous melanoma, including a patient with secondary ICI-resistant disease.

•
In dose expansion, WTX-124 in combination with pembrolizumab produced a 37.5% response rate in NSCLC for patients who had prior chemoimmunotherapy, as well as a 15.8% response rate in cutaneous melanoma for patients with prior ICI and targeted therapy, as well as a 33% response rate in patients with non-primary ICI resistant disease.

•
WTX-124 was administered safely in the outpatient setting as a monotherapy or in combination with a standard-of-care immune checkpoint inhibitor. Analysis of paired tumor biopsies from 43 patients showed that WTX-124 increased expression of T cell and T cell activation genes, consistent with increased tumor-infiltrating T cells and T cell activation, while expression of the regulatory T cell marker FOXP3 did not appear to change with WTX-124 dose.

These findings are summarized in a poster titled, "A Phase 1/1b study of the tumor-activated IL-2 prodrug WTX-124 alone or in combination with pembrolizumab in adults with relapsed/refractory, advanced/metastatic, immunotherapy-sensitive solid tumors." The late-breaking abstract was presented by Justin Moser, M.D., HonorHealth Research Institute, at SITC (Free SITC Whitepaper) on Saturday, November 7, 2026.

Werewolf has aligned with the U.S. Food and Drug Administration (FDA) on a WTX-124 recommended phase two dose (RP2D) of 18 mg IV Q2W for both monotherapy and combination with pembrolizumab. The Company believes the data support compelling opportunities for further development of WTX-124 in non-small cell lung cancer, melanoma, CSCC and gastroesophageal junction adenocarcinoma.

The Phase 1b/2 clinical trial of WTX-330 was designed to evaluate WTX-330, administered intravenously every two weeks in fixed-dose and step-up regimens, in patients with relapsed/refractory, locally advanced or metastatic solid tumors. The presentation at SITC (Free SITC Whitepaper) reported data from 24 patients treated at doses ranging from 0.016 mg/kg to 0.032 mg/kg.

Data for the Phase 1b/2 clinical trial of WTX-330 as of the May 14, 2026, clinical database lock date are summarized as follows:

•
WTX-330 was well tolerated and was administered primarily in the outpatient setting.

•
WTX-330 showed high systemic prodrug exposure with low exposure to free (active) IL-12.

•
The frequency of treatment-related adverse events was dramatically reduced at equivalent dose levels compared to what was observed with first-in-human WTX-330 material.

•
WTX-330 produced evidence of intratumoral IL-12/STAT4 signaling in 7 of 9 patients contributing paired tumor biopsies.

•
WTX-330 produced a confirmed partial response per RECIST 1.1 in a patient with gallbladder cancer whose best response to all prior standard-of-care therapy had been progressive disease, as well as multiple additional tumor regressions in patients with late-line refractory solid tumors.

These findings are summarized in a poster titled, "A Phase 1b/2 study of the tumor-activated IL-12 prodrug WTX-330 in patients with relapsed/refractory solid tumors". The poster was presented at SITC (Free SITC Whitepaper) on November 7, 2026.

Werewolf believes WTX-330 is poised for further development as a monotherapy, in combination with an ICI, or in a sequenced combination with WTX-124.

(Press release, Werewolf Therapeutics, NOV 9, 2026, View Source [SID1234674488])

On November 9, 2026 Transgene (Euronext Paris: TNG), a biotech company developing myvac, an individualized neoantigen therapeutic vaccines (INTV) platform designed to prevent cancer recurrence, alongside a portfolio of viral vector-based candidates, reported a business update on its myvac-based individualized assets TG4050 and TG4070, its upcoming plans, and its financial position as of September 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TG4050: 100% DFS sustained after more than 3 years of follow-up

Strong Phase 1 data from the randomized Phase 1/2 trial (NCT04183166), demonstrating the potential of TG4050 to prevent recurrence in patients early-stage HNSCC at high risk of relapse following surgery and (chemo)-radiotherapy, have been published in Nature Communications (see press release). TG4050 showed a favorable safety profile and induced persistent neoantigenspecific T cell responses, with a 100% disease-free survival (DFS) rate sustained after more than three years of follow-up.

The Phase 2 part of the study is ongoing. First immunological data are expected by year end, with the aim of presenting them at a scientific conference in 2027. Transgene expects to communicate topline results from TG4050’s Phase 2 trial by the end of Q1 2028.

In parallel, Transgene continues to strengthen its manufacturing capabilities in preparation for a potential Phase 3 trial in HNSCC. This includes transitioning TG4050 into a scalable cell linebased manufacturing process.

The Company remains on track to have Phase 3-ready manufacturing capacity by the end of 2027.

TG4070: all French clinical sites open, enabling patient recruitment to begin

TG4070, Transgene’s second Individualized Neoantigen Therapeutic Vaccine (INTV) candidate, represents an important strategic expansion of the myvac platform.

Combining Transgene’s own cutting-edge proprietary AI-driven technologies for neoantigen selection with scalable manufacturing capabilities, TG4070 is designed to broaden the application of individualized cancer vaccines across multiple solid tumor indications, at an early stage of the disease.

Transgene has initiated a randomized Phase 1 trial evaluating TG4070 in combination with nivolumab in patients with resected non-small cell lung cancer (NSCLC) following neoadjuvant nivolumab plus chemotherapy (EUCT 2025-520946-31-00). Five clinical sites across France are now open and recruiting, marking an important operational milestone for the study. The aim of the trial is to evaluate the potential of TG4070to prevent relapsein combination with an immune checkpoint inhibitorin patients who remain at risk of recurrence despite current treatment approaches.

Advancing programs and strategic activities

Interest in individualized neoantigen therapies for cancer has recently increased, following the ESMO (Free ESMO Whitepaper) meeting where industry reported late-stage clinical data which could confirm the viability of this approach.

Building on the clinical proof-of-principle results to date from TG4050, Transgene is actively preparing for the efficient initiation of a potential Phase 3 trial following the 2-year DFS results of the ongoing Phase 2 clinical trial, expected in Q1 2028. With TG4070 now entering clinical development, Transgene is also investigating the broader application of its myvac platform which has the potential to generate INTVs against a wide range of tumor types.

Alongside this growing momentum, Transgene continues to engage with potential partners and stakeholders.

Beyond myvac, which remains the focus of the Company, Transgene continues to evaluate the development opportunities for its broader portfolio of viral vector-based immunotherapies, including TG-MVATM and oncolytic viruses. The first patient was enrolled in the investigatorsponsored OV-PRIME-R trial, conducted in collaboration with the University of Copenhagen, evaluating BT-001 in combination with an anti-PD-1 therapy in patients with pMMR (proficient mismatch repair) localized rectal cancer (see press release).

Key financial elements

Operating income amounted to €4.3 million for the first nine months of 2026 compared to €6.1 million for the same period in 2025. It mainly consisted of the Research Tax Credit, amounting to €3.9 million, compared with €5.8 million for the same period in 2025.

As of September 30, 2026, Transgene had €84.3 million in cash, cash equivalents and other current financial assets, compared to €111.9 million as of December 31, 2025.

Transgene’s cash burn1 amounted to €29.5 million in the first nine months of 2026 compared with €28.8 million for the same period in 2025.

Under current plans, the company has sufficient cash to ensure financial visibility until early 2028.

(Press release, Transgene, NOV 9, 2026, View Source [SID1234674487])

On November 9, 2026 Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, reported that it has entered into agreements to settle an aggregate of $235,908.60 in outstanding obligations through the issuance of common shares of the Company (the "Settlement Shares") at a deemed price of $0.175 per share, based on the closing price of the Company’s common shares on November 4, 2026 (the "Debt Settlement").

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Debt Settlement comprises $125,493.70 in accrued interest owing to holders of the Company’s existing 12.0% unsecured convertible debentures and $110,414.90 in outstanding amounts payable to certain service providers.

The issuance of the Settlement Shares remains subject to all requisite regulatory approvals, including approval of the TSX Venture Exchange (the "TSXV"). All Settlement Shares issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable Canadian securities laws.

Stock Option Grant

The Company also announces that its board of directors has approved the grant of an aggregate of 124,000 stock options (the "Options") to certain directors and consultants pursuant to the Company’s Long-Term Incentive Plan.

The Options have an exercise price of $0.20 per common share, expire five years from the date of grant and vest in equal quarterly instalments over a one-year period.

(Press release, Rakovina Therapeutics, NOV 9, 2026, View Source;utm_medium=rss&utm_campaign=rakovina-therapeutics-announces-shares-for-debt-transaction [SID1234674486])